Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Early HFpEF (STADIA-HFpEF)
NCT04475042Phase 2Unknown
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF) (2 arms). Primary endpoints: Left Ventricular e' at 13 weeks and Ratio of E/e' to Left Ventricular End-Diastolic Volume Index at 13 weeks. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04475042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475042.